Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20749862 | 1.00 | CYP1A2 (0.31) | CYP1A2POLBGAA | |
| SCHEMBL25919081 | 0.97 | — | — | |
| SCHEMBL5703437 | 0.80 | — | — | |
| SCHEMBL10037076 | 0.79 | — | — | |
| SCHEMBL609517 | 0.78 | CYP1A2 (0.32) | CYP1A2POLBGAA | |
| SCHEMBL20080607 | 0.76 | — | — | |
| SCHEMBL20049944 | 0.74 | — | — | |
| SCHEMBL18542552 | 0.72 | — | — | |
| SCHEMBL13135700 | 0.72 | — | — | |
| SCHEMBL8461479 | 0.71 | TRIM24 (0.38) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150297604-A1 | Combination Products with Tyrosine Kinase Inhibitors and their Use | NOVARTIS AG (CH) | 2015-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150297604-A1 | Combination Products with Tyrosine Kinase Inhibitors and their Use | EGFR, ERBB2, ERBB3 | CYP1A2 2621/4885POLB 3783/4885GAA 1263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.